Pharma News, 2020

The U.

Taysha Gene Therapies hit the ground running when it launched this spring, cruising through a $95 million series B straight to a $100 million IPO in September.

AstraZeneca and Amgen have announced that a phase III trial of their new medicine tezepelumab failed to meet the primary endpoint in patients with severe, oral corticosteroid-dependent asthma.

AMSTERDAM (Reuters) - The European Union geared up to start mass vaccinations against COVID-19 just after Christmas after the shot developed by Pfizer and its German partner BioNTech cleared r...

Construction of the third plant of BeiGene Ltd, a Chinese biotechnology company, along with the completion of its second plant in Guangzhou, the capital of Guangdong province, will help boost the comp...

The European Commission (EC) has approved Aimmune Therapeutics’ Palforzia, making it the first treatment for peanut allergy in the EU, according to the firm.

Neurogene has raised $115 million in a second-round financing that will accelerate its plans to start clinical trials of a range of gene therapies for inherited neurological diseases, initially focusi...

Agios Pharmaceuticals’ roots are in cancer drug development, but it’s passing that baton to Servier as it doubles down on its programs in genetically defined diseases, including a drug it’s deve...

Moderna has been approved by the US government as the country's second Covid-19 vaccine, clearing the way for millions of doses to be released.

Danish pharma company Novo Nordisk has submitted a marketing authorisation application the European Medicines Agency (EMA), seeking approval for once-weekly semaglutide for weight management.

An international consortium, led by Cambridge Medical Research Council (MRC) researchers, has developed an ‘open platform’ to advance and prioritise drug discovery and repurposing efforts ...

TOKYO (Kyodo) -- U.